Reuters logo
in 7 months
BRIEF-Boehringer Ingelheim biosimilar candidate to Humira accepted for EMA and FDA regulatory review
January 18, 2017 / 2:32 PM / in 7 months

BRIEF-Boehringer Ingelheim biosimilar candidate to Humira accepted for EMA and FDA regulatory review

Jan 18 (Reuters) - Boehringer Ingelheim

* Boehringer Ingelheim biosimilar candidate to Humira accepted for EMA and FDA regulatory review

* Boehringer Ingelheim says BI 695501 has been accepted for regulatory review by European Medicines Agency and U.S FDA Source text for Eikon: (bit.ly/2jwFiK3) Further company coverage: [Boehringer Ingelheim]

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below